Policy & Regulation
Bridger Named to Expansion Therapeutics Board of Directors
19 January 2022 - - US-based biotechnology company Expansion Therapeutics, Inc has appointed Gary Bridger, Ph.D., to its board of directors, serving as an independent director, the company said.

Dr. Bridger has more than 30 years of experience in research and development and a breadth of management and operational experience, having served in senior leadership positions and on the boards for several leading biotechnology and pharmaceutical companies.

He currently serves as interim chief scientific officer and independent board member for Liminal Biosciences, as well as an independent board member for X4 Pharmaceuticals.

Most recently, Dr. Bridger served on the board of directors for Aquinox Pharmaceuticals from 2015 until the company merged with Neoleukin Therapeutics in 2019.

Prior to that, he was managing director at Five Corners Capital, where he was involved in several initial public offerings on the NASDAQ for portfolio companies, including Alder Biopharmaceuticals, Aquinox Pharmaceuticals, Celator Pharmaceuticals, MacroGenics Inc., and Xenon Pharmaceuticals.

He also has served on the boards for Alder, Aquinox, Neuraxon Inc. and was a board observer for Celator and Presidio Pharmaceuticals.

Before joining Five Corners Capital, Dr. Bridger was executive vice president of Research and Development for Xenon Pharmaceuticals Inc., developing innovative therapies for neurological disorders, including epilepsy.

Previously, he served as a partner at Ventures West Capital Management where he provided scientific and operational expertise to life sciences companies.

Dr. Bridger has also held senior positions at Genzyme Corp. and AnorMED Inc. While at Genzyme, he was directly involved in the successful regulatory filing, approval and launch of Mozobil(plerixafor), in the US, Europe and Canada.

He began his pharmaceutical career at Johnson Matthey Pharmaceutical Research.

Dr. Bridger received his B.Sc. in Chemistry and his Ph.D. in Synthetic Organic Chemistry from the University of Manchester Institute of Science and Technology (UMIST), in Manchester, UK. He completed his post-doctoral research fellowship in Organic Chemistry at Boston College.

He has authored more than 90 peer-reviewed publications and has over 40 issued patents.

Expansion Therapeutics is a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases including neurodegenerative disorders.

Based on exclusive worldwide rights to groundbreaking research from the laboratory of Matthew D. Disney, Ph.D., at Scripps Research, Expansion has assembled the intellectual property, know-how, and proprietary enabling technologies and tools necessary to facilitate the creation of potent and specific small molecule RNA modulators.

Through this platform, Expansion is building a portfolio of novel RNA-targeted drug candidates with activity across a broad number of severe RNA-mediated disease indications.

Headquartered in Boston, Massachusetts, Expansion's research facility is located in Jupiter, Florida.